Presence/absence of HSV oral lesions · Patients being treated for cancer (predominantly haematological malignancies)
Prophylactic aciclovir (oral or intravenous) showed no clear difference in presence/absence of HSV oral lesions compared with prophylactic valaciclovir (oral); GRADE not reported.
1 finding from 1 review
Presence/absence of HSV oral lesions · Patients being treated for cancer (predominantly haematological malignancies)
Prophylactic aciclovir (oral or intravenous) led to lower presence/absence of HSV oral lesions compared with placebo; GRADE not reported.
1 finding from 1 review
Length of hospital stay · Patients being treated for cancer (predominantly haematological malignancies)
The review found no eligible studies for this question.
1 finding from 1 review
Recurrence of lesions · Patients being treated for cancer (predominantly haematological malignancies)
The review found no eligible studies for this question.
1 finding from 1 review
Cost of oral care · Patients being treated for cancer (predominantly haematological malignancies)
1 finding from 1 review
Only one trial reported on the cost of prophylaxis for HSV (Liesveld 2002). The reported mean pharmacy costs for those randomised to receive aciclovir were $1080 compared to $320 for those initially randomised to…
1 study · 30 participants
GRADE not reported
Adverse effects · Patients being treated for cancer (predominantly haematological malignancies)
1 finding from 1 review
Proportion of people with hospital admissions (from the emergency room) · acute exacerbations of chronic obstructive pulmonary disease
Intravenous magnesium sulfate + standard care may leads to lower proportion of people with hospital admissions (from the emergency… compared with placebo + standard care (low certainty).
1 finding from 1 review
Proportion of people requiring non‐invasive ventilation · acute exacerbations of chronic obstructive pulmonary disease
It is very uncertain whether intravenous magnesium sulfate + standard care changes proportion of people requiring non‐invasive ventilation compared with placebo + standard care (very low certainty).
1 finding from 1 review
Proportion of people with serious adverse events · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Length of hospital stay · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Change in oxygen saturation (SaO2) · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Change in dyspnoea score · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Oral mucositis (any severity) · Children with acute lymphoblastic leukaemia receiving chemotherapy alone
Keratinocyte growth factor (KGF), intravenous led to lower oral mucositis (any severity) compared with chlorhexidine mouthwash; GRADE not reported.
1 finding from 1 review
Oral mucositis (moderate to severe) · Children with acute lymphoblastic leukaemia receiving chemotherapy alone
Keratinocyte growth factor (KGF), intravenous led to lower oral mucositis (moderate to severe) compared with chlorhexidine mouthwash; GRADE not reported.
1 finding from 1 review
Oral mucositis (severe) · Children with acute lymphoblastic leukaemia receiving chemotherapy alone
Keratinocyte growth factor (KGF), intravenous led to lower oral mucositis (severe) compared with chlorhexidine mouthwash; GRADE not reported.
1 finding from 1 review
Time to complete healing · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
1 finding from 1 review
Two studies. Median time to total healing was shorter for patients receiving oral or intravenous aciclovir than placebo: median of 8 days versus 21 days, P = 0.01 (Shepp 1985); 13.9 days versus 20.7 days, P = 0.08…
2 studies
GRADE not reported
Recurrence of lesions · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
The review found no eligible studies for this question.
1 finding from 1 review
For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
0 studies
No studies found
Duration of viral shedding · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
1 finding from 1 review
Relief of pain · Patients being treated for cancer with established oral HSV infection (bone marrow transplant recipients / immunocompromised)
1 finding from 1 review